Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
grade F 5.16 -0.58% -0.03
NERV closed down 0.58 percent on Friday, November 15, 2019, on 87 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical NERV trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Weak + Overbought Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Weak, Overbought and Reversal Signs Reversal 0.00%
Overbought Stochastic Strength 0.00%
Weak + Overbought Other -0.58%
Wide Bands Range Expansion -0.58%
Overbought Stochastic Strength -0.58%
Weak + Overbought Other -0.19%

Older signals for NERV ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Drugs Parkinson's Disease Schizophrenia Psychoactive Drugs Neurochemistry Treatment Of Parkinson's Disease Major Depressive Disorder Ketones Antidepressants Central Nervous System Diseases Treatment Of Major Depressive Disorder Treatment Of Central Nervous System Diseases
Is NERV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.12
52 Week Low 4.01
Average Volume 376,017
200-Day Moving Average 6.5483
50-Day Moving Average 5.7755
20-Day Moving Average 4.711
10-Day Moving Average 5.112
Average True Range 0.2886
ADX 26.01
+DI 24.6807
-DI 17.982
Chandelier Exit (Long, 3 ATRs ) 4.5142
Chandelier Exit (Short, 3 ATRs ) 4.8758
Upper Bollinger Band 5.6203
Lower Bollinger Band 3.8017
Percent B (%b) 0.75
BandWidth 38.603269
MACD Line -0.0163
MACD Signal Line -0.1555
MACD Histogram 0.1392
Fundamentals Value
Market Cap 219.35 Million
Num Shares 42.5 Million
EPS -1.08
Price-to-Earnings (P/E) Ratio -4.78
Price-to-Sales 0.00
Price-to-Book 2.36
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.39
Resistance 3 (R3) 5.39 5.32 5.35
Resistance 2 (R2) 5.32 5.26 5.32 5.33
Resistance 1 (R1) 5.24 5.23 5.21 5.24 5.32
Pivot Point 5.17 5.17 5.15 5.17 5.17
Support 1 (S1) 5.09 5.11 5.06 5.09 5.00
Support 2 (S2) 5.02 5.08 5.02 4.99
Support 3 (S3) 4.94 5.02 4.97
Support 4 (S4) 4.94